HeartStent gets funds for revolutionary coronary device
This article was originally published in Clinica
HeartStent, a development-stage medical device company with a device which it hopes could redefine the coronary artery disease market and cut many hundreds of million dollars from annual healthcare costs worldwide, has raised $12.8 million in private financing in order to continue development of the revolutionary device.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.